Pyxis Oncology grants CEO 2.5M stock options

Pyxis Oncology granted its CEO and chairman a large four-year vesting stock option award with a $3.89 exercise price.

Rhea-AI Filing Summary

Pyxis Oncology, Inc. (PYXS) reported that CEO and Chairman Thomas Civik received a grant of stock options covering 2,503,050 shares of common stock on September 4, 2026. The options have an exercise price of $3.89 per share and expire on September 4, 2036. The award vests over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments, subject to his continued employment. No Rule 10b5-1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 2,503,050 shares

Grant/Award 1 txn

Insider Civik Thomas

Role CEO & Chairman of the Board

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	2,503,050	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,503,050 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

Key Figures

Option shares granted: 2,503,050 shares Exercise price: $3.89 per share Total options held after grant: 2,503,050 options +3 more

6 metrics

Option shares granted 2,503,050 shares Stock options to buy Pyxis Oncology common stock granted to CEO on September 4, 2026

Exercise price $3.89 per share Exercise price for the 2,503,050 stock options granted

Total options held after grant 2,503,050 options Total derivative securities following this reported transaction

Vesting cliff 25% after one year 25% of the options vest on the first anniversary of September 4, 2026

Remaining vesting period 36 monthly installments Remaining 75% of options vest in 36 equal monthly installments thereafter

Option expiration date September 4, 2036 Expiration date of the CEO’s stock options

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security titled "Stock Option (Right to Buy)" was granted to the CEO"

exercise price financial

"The options have an exercise price of $3.89 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option will vest over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"The options expire on September 4, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

What equity award did the CEO of PYXS receive on September 4, 2026?

CEO and Chairman Thomas Civik received a stock option grant for 2,503,050 shares of Pyxis Oncology common stock on September 4, 2026, as reported in the Form 4.

What is the exercise price of the new Pyxis Oncology (PYXS) CEO stock options?

The stock options granted to the CEO have an exercise price of $3.89 per share, allowing the purchase of up to 2,503,050 shares of Pyxis Oncology common stock at that price.

How do the PYXS CEO’s new stock options vest?

The options vest over four years: 25% vests on the first anniversary of September 4, 2026, and the remaining 75% vests in 36 equal monthly installments, subject to continued employment through each vesting date.

When do the newly granted PYXS stock options expire?

The stock options granted to the CEO and Chairman expire on September 4, 2036, giving a 10-year term from the grant date, as disclosed in the Form 4.

Were the PYXS CEO option grants made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not selected, meaning no Rule 10b5-1 trading plan is reported in connection with this stock option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:41 AM Accepted by SEC EDGAR 09/08/2026 - 07:41 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Civik Thomas

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman of the Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.89	09/04/2026		A		2,503,050		(1)	09/04/2036	Common Stock	2,503,050	$0	2,503,050	D

Explanation of Responses:

1. The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Thomas Civik	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)